MDM2 Drives Proteasome Inhibitor Resistance and Represents a TP53-Independent Therapeutic Vulnerability in Multiple Myeloma

Proteasome inhibitors (PIs) are central to multiple myeloma (MM) therapy; however, resistance remains a major clinical challenge, particularly in relapsed/refractory disease. To identify functional mediators of carfilzomib (CFZ) resistance, we performed complementary gain-of-function CRISPR activati...

Celý popis

Podrobná bibliografie

Hlavní autoři:	María Labrador, Sara Cozzubbo, Mariangela Porro, Michela Cumerlato, Cecilia Bandini, Elisabetta Mereu, Tina Paradzik, Benedetta Donati, Veronica Manicardi, Domenica Ronchetti, Mattia D’Agostino, Alessandra Larocca, Francesca Gay, Benedetto Bruno, Alessia Ciarrocchi, Andrew Chatr-Aryamontri, Antonino Neri, Eugenio Morelli, Roberto Piva
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	MDPI AG 2026-05-01
Edice:	Cells
Témata:	MDM2 multiple myeloma proteasome inhibitors <i>TP53</i> drug resistance synthetic lethality
On-line přístup:	https://www.mdpi.com/2073-4409/15/9/831
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!